Journal Club - Recent Additions

March - 2013

Previous Next    

Showing Journal 2 of 13

Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis - The ACCESS Randomized Trial

the ACCESS Study Group JAMA, 2013, 309(11):1154-1162


This randomised RCT examines the effect of Eritoran in patients with sepsis.If, like me, you dont know anything about Eritoran, it is a synthetic lipid A antagonist that blocks LPS binding at the cell surface MD2-TLR4 receptor. As LPS is a big factor in gram negative bacteria activity and...


Previous Comments

I guess to do it in sepsis within 12 hours, you're not going to know if they have gram negative sepsis until its too late...
Con-23 Mar, 2013 12:54:13 PM